Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
NEW YORK, Jan. 09, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Illumina, Inc. (NASDAQ:ILMN) securities between July 26, 2016 and October 10, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/illumina-inc-ilmn. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants failed to disclose that: (1) Illumina was suffering a large decline in its instrument sales; (2) this decline was damaging Illumina’s revenue; (3) Illumina lacked visibility into trends that could have a substantial impact on its financial results; (4) as such, Illumina’s revenue guidance was unreliable and overstated; and (5) consequently, Illumina’s statements concerning its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On October 10, 2016 Illumina announced disappointing financial results for the third quarter of fiscal year 2016. The company had predicted revenues of $625 to $630 million for the quarter. However, citing “declining demand for its high-speed genetic sequences” Illumina generated just $607 million. Following this news, Illumina stock dropped as much as 25% during intraday trading on October 11, 2016.
If you suffered a loss in Illumina you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/illumina-inc-ilmn.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
